Division of Edwards Lifesciences Corp.
Latest From BMEYE BV
ClearSight is intended to reduce the risk of post-surgical complications by non-invasively monitoring blood volume and flow based on information gathered by a small finger cuff with an infrared sensor.
According to a panel of strategic investors speaking at a recent IN3 meeting, structured deals that can help manage risk for medtech start-ups seeking funding and strategics looking for growth opportunities are on the rise.
In February, Cheetah Medical Inc. raised $9 million in a late financing round to support commercialization of its noninvasive, continuous hemodynamic monitoring system. It’s a product sector that’s received lots of attention recently, driven by rising cost pressures on hospitals, demographics, and new noninvasive alternatives to conventional hemodynamic monitoring technologies that require the insertion of an arterial line or pulmonary artery catheter.
In February, Cheetah Medical Inc. raised $9 million in a late financing round to support commercialization of its noninvasive, continuous hemodynamic monitoring system. It’s a product sector that’s received lots of attention recently.
- Monitoring Equipment & Devices
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Western Europe
- Parent & Subsidiaries
- Edwards Lifesciences Corp.
- Senior Management
Frank Wittgen, CFO
Dominic Spadafore, VP, Global Sales & Mktg.
Joeroen van Goudoever, PhD, VP, Research
Rienco Verschelling, VP, Dev. & Engineering
- Contact Info
Phone: (31) 20 751 2410
Centerpoint 1, 4th Fl.
Hoogoorddreef 60, 1101 BE
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.